Tag Archives: opdivo

Mesothelioma Tumor Response to Nivolumab Detailed in New Case Study

mesothelioma tumor response to nivolumab

An Indian woman in still alive two years after a mesothelioma diagnosis thanks to a remarkable mesothelioma tumor response to nivolumab. Nivolumab is sold under the brand name Opdivo. It is a type of immunotherapy. Nivolumab is sometimes used for lung cancer that progresses after chemotherapy. A hospital in Mumbai tried nivolumab on a pleural mesothelioma patient after several types of chemotherapy did not work. Doctors say the mesothelioma tumor response to nivolumab was so great that the patient no longer needed supplemental oxygen.  Opdivo in Mesothelioma Treatment Opdivo is not FDA-approved for mesothelioma treatment. Only Alimta (pemetrexed) holds that designation. But pleural mesothelioma grows quickly and is hard to treat. Even the gold standard therapies often do not work … Continue reading Mesothelioma Tumor Response to Nivolumab Detailed in New Case Study »

New Mesothelioma Immunotherapy Trial Now Underway at Baylor

mesothelioma immunotherapy trial

Cancer researchers at Baylor College of Medicine have launched a new mesothelioma immunotherapy trial. The trial combines the cancer drug Opdivo (nivolumab) with injections of a modified virus called MTG201. Baylor scientists are hoping to recruit 12 pleural mesothelioma patients whose cancer has come back after chemotherapy.  The treatment combination appeared to work well in mice with mesothelioma. If it works as well in people, this new mesothelioma immunotherapy trial could change the outlook for many people with malignant mesothelioma.  How the New Mesothelioma Immunotherapy Trial Will Work Opdivo is the brand name for nivolumab. It blocks a protein called PD-1 in cancer cells. PD-1 is one of the ways that mesothelioma cells evade the immune system. Opdivo is often … Continue reading New Mesothelioma Immunotherapy Trial Now Underway at Baylor »

Mesothelioma Immunotherapy Drug Keytruda Gets a Boost from Opdivo Study

mesothelioma immunotherapy drug

The company that makes a promising new mesothelioma immunotherapy drug got a boost from a competitor’s study this week.  The makers of the lung cancer drug Opdivo have released some disappointing results from their latest lung cancer trial. The findings present another setback for Bristol-Myers Squibb.  But they are good news for Merck, the maker of the mesothelioma immunotherapy drug Keytruda. In the wake of the publication, Merck’s stocks rose while Bristol-Myers’ dropped.  How Opdivo Works Opdivo is the brand name for nivolumab. It is a monoclonal antibody that blocks PD-1. PD-1 is a cell surface protein expressed by some lung cancer and mesothelioma tumors. An Australian study estimated that more than 72 percent of mesothelioma patients overexpress PD-1. Opdivo … Continue reading Mesothelioma Immunotherapy Drug Keytruda Gets a Boost from Opdivo Study »